Victory Capital Management Inc Infinity Pharmaceuticals, Inc. Transaction History

Victory Capital Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$0.49 - $1.2 $29 - $73	-61 Reduced 0.52%	11,649 $7,000
Q1 2022 May 04, 2022	SELL	$0.85 - $2.4 $393 - $1,111	-463 Reduced 3.8%	11,710 $9,000
Q4 2021 Feb 07, 2022	SELL	$1.86 - $3.36 $626 - $1,132	-337 Reduced 2.69%	12,173 $27,000
Q3 2021 Nov 02, 2021	SELL	$1.52 - $3.82 $1,156 - $2,907	-761 Reduced 5.73%	12,510 $43,000
Q2 2021 Aug 03, 2021	BUY	$2.66 - $3.47 $319 - $416	120 Added 0.91%	13,271 $40,000
Q1 2021 May 04, 2021	BUY	$1.98 - $5.36 $6,019 - $16,294	3,040 Added 30.07%	13,151 $42,000
Q4 2020 Feb 01, 2021	BUY	$1.05 - $2.77 $10,616 - $28,007	10,111 New	10,111 $21,000
Q2 2020 Aug 07, 2020	SELL	$0.77 - $1.13 $7,201 - $10,567	-9,352 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$0.69 - $1.52 $99 - $218	-144 Reduced 1.52%	9,352 $8,000
Q4 2019 Feb 04, 2020	SELL	$0.88 - $1.29 $122 - $179	-139 Reduced 1.44%	9,496 $13,000
Q3 2019 Nov 12, 2019	BUY	$1.03 - $1.75 $9,924 - $16,861	9,635 New	9,635 $10,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.